Abstract
Chemotherapy-induced anemia is the predominant adverse event observed in individuals undergoing cancer treatment, resulting in a reduction in red blood cells and hemoglobin levels. This condition manifests through indicators such as diminished quality of life and fatigue. Effective approaches for managing recurrent chemotherapy-induced anemia encompass the use of erythropoietin-stimulating agents, blood transfusions, and intravenous iron supplementation. Each of these interventions presents distinct pros and cons, with selecting a particular treatment modality contingent upon the severity of anemia and the duration of malignancy. A comprehensive review of scholarly literature reveals a high prevalence of anemia among cancer patients receiving chemotherapy. Ongoing research endeavors are focused on developing pharmacological agents for cancer treatment that are devoid of adverse effects, particularly concerning anemia, a common complication associated with this therapeutic approach.
Publisher
Sağlık Bilimleri Üniversitesi, Bursa Tıp Fakültesi
Reference137 articles.
1. 1Radziwon P, Krzakowski M, Kalinka E, Zaucha R, Wysocki P, Kowalski D, Gryglewicz J, Wojtukiewicz MZ. Anemia in cancer patients—Expert Group recommendations. Revision 2020. Hematology in Clinical Practice. 2020;11(1):1-11.
2. Van Belle SJ-P, Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Critical reviews in oncology/hematology. 2003;47(1):1-11.
3. Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and treatment of cancer‐related anemia. American journal of hematology. 2014;89(2):203-12.
4. Langer CJ, Choy H, Glaspy JA, Colowick A. Standards of care for anemia management in oncology: focus on lung carcinoma. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2002;95(3):613-23.
5. Kano Y, Kajiwara K, Kozai YJTAJotMS. Cancer-related Microangiopathic Hemolytic Anemia2023;365(2):e15-e6.